Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

An iCare Urgent Care facility just opened in Altoona and is taking both scheduled and walk-in patients. It’s located at 701 ...

HUNTSVILLE, Ala. (WHNT) – According to HEMSI, a man was injured on Wednesday when a car fell on top of him. HEMSI ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

FY25 consensus $4.69. Raises FY25 revenue view to $1.15B-$1.225B from $1.095B-$1.17B, consensus $1.16B.Stay Ahead of the Market:Discover ...

Halozyme backs FY24 adjusted EPS view $4.00-$4.20, consensus $4.14 Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.